[
  {
    "ts": null,
    "headline": "Waters Corp. stock rises Friday, still underperforms market",
    "summary": "Waters Corp. stock rises Friday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=330511a978ee3bc06aad4567e367b5a4ed912f25e176766129375f6a32414bdf",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735924260,
      "headline": "Waters Corp. stock rises Friday, still underperforms market",
      "id": 132337748,
      "image": "",
      "related": "WAT",
      "source": "MarketWatch",
      "summary": "Waters Corp. stock rises Friday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=330511a978ee3bc06aad4567e367b5a4ed912f25e176766129375f6a32414bdf"
    }
  },
  {
    "ts": null,
    "headline": "Waters price target raised to $390 from $372 at Evercore ISI",
    "summary": "Evercore ISI raised the firm’s price target on Waters (WAT) to $390 from $372 and keeps an In Line rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group. Published first on TheFly – the ultimate source for real-ti",
    "url": "https://finnhub.io/api/news?id=eb5c81e92a6c592bdf6c4b26e945732aaa6a0d24e5c0f6e8da2bc994e85d17cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735905031,
      "headline": "Waters price target raised to $390 from $372 at Evercore ISI",
      "id": 132252398,
      "image": "",
      "related": "WAT",
      "source": "Yahoo",
      "summary": "Evercore ISI raised the firm’s price target on Waters (WAT) to $390 from $372 and keeps an In Line rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group. Published first on TheFly – the ultimate source for real-ti",
      "url": "https://finnhub.io/api/news?id=eb5c81e92a6c592bdf6c4b26e945732aaa6a0d24e5c0f6e8da2bc994e85d17cc"
    }
  }
]